Industry Reports
Global Drug Market Will Reach Nearly $1.5 Trillion in 2021
Total spending on medicines is forecast to reach $1.5 trillion by 2021, up 33 percent from 2016 levels, even as annual growth moderates from the record pace set in 2014 and 2015, according to new research released by the...
Industry Reports
Novartis announces phase II SUSTAIN study of SEG101 significantly reduces frequency of sickle cell pain crises
Results from the Phase II SUSTAIN study show that SEG101 (crizanlizumab, formerly SelG1), an anti-P-selectin antibody, reduced the median annual rate of sickle cell-related pain crises (SCPC) by 45.3% compared to placebo (1.63 vs 2.98, p=0.010) in patients with...
Industry Reports
Aegerion Pharmaceuticals INC and QLT INC Complete Merger Transaction ; QLT to Change Name to Novelion Therapeutics Inc
Aegerion Pharmaceuticals Inc and QLT Inc announced the completion of their merger transaction, as a result of which Aegerion is now an indirect wholly-owned subsidiary of QLT. In conjunction with the closing of the merger, QLT changed its name...
Industry Reports
Catalent Acquires Accucaps To Expand Softgel Development And Manufacturing Capabilities And Capacity
Catalent Inc the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products announced that it has agreed to acquire Accucaps Industries Limited (Accucaps). The Canada-based developer and manufacturer of...
Industry Reports
Arrow Generiques to acquire select assets in France from Teva
Arrow Generiques SAS, the French subsidiary of Aurobindo Pharma Ltd announced the signing of an agreement to acquire select commercial products in France from Teva. Arrow Generiques will acquire the right, title and interest in products...
Industry Reports
GSK Starts Phase III Programme with Daprodustat for Anemia Associated with Chronic Kidney Disease
GlaxoSmithKline plc announced the start of a phase III development programme investigating daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a treatment for anaemia associated with chronic kidney disease (CKD). The phase III programme...
Industry Reports
Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
Eli Lilly and Company announced that solanezumab did not meet the primary endpoint in the EXPEDITION3 clinical trial, a phase 3 study of solanezumab in people with mild dementia due to Alzheimer's disease (AD). Patients treated...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read